Drug development
Toxicology knowledge Team Sweden AB
Drug Project Support
Introduction:
Toxicological evaluation of drug candidates are subjected to regulatory guidelines to ensure human safety in clinical trials. To optimise project sucess, it is important to involve toxicological expertise early on. Expert planning of the toxicology program and each part of the program, gives the project freedom to operate within the regulatory framework, and a greater chance of proceeding into clinical trials and beyond.
With detailed planning of the toxicology studies by using the right species, setting the right doses and, above all, with proper risk assessment of findings in each phase of the development, the project saves time and resources. In the right context and assessed by the right expertise, a toxicological finding is usually not a stopper for the project to proceed into the next phase of development.
“We thought the adverse effects would be a stopper for the project, but with the help of TKT’s assessment and paticipation in a scientific advise meeting, the project could progress into the next phase”
We know from our long experience in drug development, that by involving TKT expertise early on, many issues can be resolved proactively during the process, without causing delay or increased costs.
With an experienced toxicologist involved throughout the drug development process, there is a higher chance for acceptance of the toxicological safety assessment in INDs, IMPDs, IBs NDAs and scientific advice.
Our many years of hands-on experience as study directors show that early toxicology studies (those run before Phase 1) almost never end up according to a predetermined template. Bespoke adaptation to specific circumstances of a project is always needed. TKT can help with project-specific adaptation of studies, to ensure best possible value from each study performed.
“It was a relief to have acess to TKT’s experience since this was the first time up to and beyond Phase 1 for our company”
Common queries to TKT
Client: “In retroperspective, I wish we had contcacted TKT much earlier”
Toxicological expertise is vital in all parts of drug development, but the engagement varies, depending on developmental stage, project type, indication, adverse findings etc. Therefore, we advise you to discuss your project with us, to help you set up a reasonable and realistic plan for your project’s specific needs.
For small molecule pharmaceuticals, and naturally within limits, it is better to have all probable impurities present in the toxicology studies. The reason is that all impurities present in the clinical batches must have been adequately “qualified”/safety assessed in early pivotal tox studies. Otherwise, additional studies might be requested from authorities, which may cause substantial interruption in the development.
Learn more – take part in our workshops. Tailor-made to fit your needs:
Contact us
Client: “I incorrectly assumed that the toxicology study program prior to Phase 1 was more or less generic”
